Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Arimoclomol

13 evidence topics · 14 sources

Phase 2/3 trial NPC-002: prespecified 5-domain NPCCSS primary endpoint

“In a 12‐month, prospective, randomised, double‐blind, placebo‐controlled, phase 2/3 trial (ClinicalTrials.gov identifier: NCT02612129), patients (2‐18 years) were randomised 2:1 to arimoclomol:placebo, stratified by miglustat use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary endpoint was change in 5‐domain NPC Clinical Severity Scale (NPCCSS) score from baseline to 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fifty patients enrolled; 42 completed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At month 12, the mean progression from baseline in the 5‐domain NPCCSS was 0.76 with arimoclomol vs 2.15 with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A statistically significant treatment difference in favour of arimoclomol of −1.40 (95% confidence interval: −2.76, −0.03; P = .046) was observed, corresponding to a 65% reduction in annual disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the prespecified subgroup of patients receiving miglustat as routine care, arimoclomol resulted in stabilisation of disease severity over 12 months with a treatment difference of −2.06 in favour of arimoclomol (P = .006).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Adverse events occurred in 30/34 patients (88.2%) receiving arimoclomol and 12/16 (75.0%) receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Fewer patients had serious adverse events with arimoclomol (5/34, 14.7%) vs placebo (5/16, 31.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Treatment‐related serious adverse events (n = 2) included urticaria and angioedema.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Phase 2/3 trial NPC-002: results in the miglustat subgroup in the prescribing information
R4DNPCCSS scoreMIPLYFFA with miglustat (N=26 at baseline, N=22 at month 12)Placebo with miglustat (N=13 at baseline, N=12 at month 12)
Baseline, mean (SD)“8.9 (6.1)”“7 (5.8)”
Change from baseline to month 12, mean (SD)“-0.2 (1)”“1.9 (3.4)”
Change from baseline to month 12, LS mean (SE)“-0.2 (0.5)”“2 (0.7)”
Placebo-subtracted difference (95% CI)“-2.2 (-3.8, -0.6)”Not applicable
Regulatory status outside the United States: refusal of European Union marketing authorisation confirmed in November 2026